NCT04919811Phase 2Active not recruiting

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Study sponsor: Nuvation Bio Inc. · NUVB

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-06-11Actual
Enrollment · participants217Actual
Source updated2026-01-07Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview